Patient Flow Articles & Analysis
27 news found
Instylla is now enrolling patients in a clinical trial for the world’s first hydrogel-based liquid embolic intended for the treatment of hypervascular tumors. ...
The objectives of the recently concluded explorative Phase II study included investigating the safety profile of GS-248, its ability to inhibit mPGES-1, as well as its effect on Raynaud's phenomenon and peripheral blood flow in systemic sclerosis patients. In total, 69 patients were included and received either 120 mg of GS-248, or placebo, once ...
The VenoValve is intended to restore proper directional blood flow for patients with CVI of the deep veins of the leg. CVI occurs when the natural valves inside of the veins fail, causing blood to flow in the wrong direction (reflux), and creating increased pressure inside of the veins of the leg (venous hypertension). ...
Already in the first stages of the disease, patients are affected by episodes of reduced blood flow in fingers and toes. ...
The VenoValve is intended to restore proper directional blood flow for patients with CVI of the deep veins of the leg. CVI occurs when the natural valves inside of the veins fail, causing blood to flow in the wrong direction (reflux), and creating increased pressure inside of the veins of the leg (venous hypertension). ...
The VenoValve is intended to restore proper directional blood flow for patients with CVI of the deep veins of the leg. CVI occurs when the natural valves inside of the veins fail, causing blood to flow in the wrong direction (reflux), and creating increased pressure inside of the veins of the leg (venous hypertension). ...
Synairgen plc (LSE: SNG), the respiratory company developing SNG001, a formulation for inhalation containing the broad-spectrum antiviral protein interferon beta, today announces that the international Phase 3 SPRINTER trial of SNG001 in patients hospitalised with COVID-19 did not meet its primary or key secondary efficacy endpoints. SNG001 demonstrated a favourable safety profile and was well ...
Athenson continued, “We are now much closer to improving the lives of 1.2M patients battling severe COPD and ILD (pulmonary fibrosis) and who struggle with each breath to perform the day-to-day activities that most people take for granted. ...
In the study, 72% of TearCare patients showed OSDI improvement by at least one severity category, and 81% of TearCare patients met Miller’s definition of clinically meaningful improvement in OSDI. ...
The patient-friendly UPRIGHT MRI has a near-zero patient claustrophobic rejection rate. ...
There is currently no FDA approved therapeutic available for NASH and liver fibrosis patients. Under the terms of the original agreement, HemoShear received upfront payments and R&D funding, and Takeda received exclusive access to HemoShear’s proprietary disease modeling platform to discover and develop best-in-class therapeutics for specific liver diseases. ...
It is thanks to the UPRIGHT® MRI’s ability to scan patients in weight-bearing positions, as well as in the recumbent, non-weight-bearing position, that we are finding significant postural differences in CSF flow. These differences may provide clues that enable physicians to find solutions to their patients’ medical problems. ...
Lumos Diagnostics (ASX: LDX), a leader in rapid point-of-care (POC) diagnostic technologies, today announced that the Emergency Department at Box Hill Hospital in Melbourne, Australia, has initiated a 300-subject investigator-led trial using Lumos’ FebriDx® POC test to rapidly identify patients presenting with a suspected viral infection consistent with COVID-19. This ...
Throughout the study, the device provided pulsatile blood flow, synchronized with the native heart, without the use of sensors. This pulsatile operation is intended to reduce the complications associated with current devices which produce constant blood flow, resulting in patients not having a pulse. The ASAIO1 (American Society for Artificial ...
ByCorWave
The new software suite, along with the company’s interoperable imaging module, ActivSight™, are the first commercially-available products of the ActivEdge™ platform, which is being designed to transform massive amounts of data gathered intra-operatively to provide surgeons real-time guidance in the operating room. The ability to detect blood flow is critical in ...
This is the result of a study in an investigator initiated study in patients carried out with the German Center for Heart and Circulation Research (DZHK). ...
The patient-friendly UPRIGHT MRI has a near-zero patient claustrophobic rejection rate. ...
“This breakthrough technology will, for the first time, enable non-invasive on-demand Doppler measurement of blood flow, which we believe will be an essential tool for the medical ...
Gesynta Pharma AB today announced that the first patients have been dosed in a Phase II study of its oral drug candidate GS-248 in patients with systemic sclerosis - a debilitating autoimmune disease that causes serious damage to the microvasculature. This proof-of-concept study will investigate the safety of GS-248 and its efficacy on Raynaud's phenomenon and ...
Many patients treated in hospitals or staying in long-term care facilities have conditions that make them much more susceptible to infections due to microbial pathogens, including mold. ...